Live Breaking News & Updates on Ev 302 keynote a39 study

Stay updated with breaking news from Ev 302 keynote a39 study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Japanese Approval Sought for Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

A sNDA seeking approval of enfortumab vedotin plus pembrolizumab for first-line use in patients with urothelial cancer has been submitted to Japan’s MHLW. ....

Japan , European-medicines-agency , Astellas-pharma-inc , Japan-ministry-of-health , Medicines-agency , Enfortumab-vedotin , Padcev , Pembrolizumab , Keytruda , Urothelial-cancer , Supplemental-new-drug-application